MARINUS is a leader in the development of neurosteroids for the treatment of depression. It is developing ganaxolone for PPD (Postpartum Depression).
Topline data from a Phase 2 study should be available in H2.
The stock price dropped after its Q earnings results. Its cash of $21.47M is solid to fund its operations and this is good for me.
Technically the recent move down is within a 5 waves up pattern and I remain bullish. Price is testing the two important lines (long term EMAs)
Therefore I am positive for this stock with a Target to the upside which is now set at the $10-12 area.
Current prices are attractive for building a position at MRNS.
Protection: A move below $5 will cancel the positive scenario and therefore this is the stop loss.
An alternative Strategy: Instead of buying at current levels, wait until price strengthens, Buy above $7.5 with same target prices.
Topline data from a Phase 2 study should be available in H2.
The stock price dropped after its Q earnings results. Its cash of $21.47M is solid to fund its operations and this is good for me.
Technically the recent move down is within a 5 waves up pattern and I remain bullish. Price is testing the two important lines (long term EMAs)
Therefore I am positive for this stock with a Target to the upside which is now set at the $10-12 area.
Current prices are attractive for building a position at MRNS.
Protection: A move below $5 will cancel the positive scenario and therefore this is the stop loss.
An alternative Strategy: Instead of buying at current levels, wait until price strengthens, Buy above $7.5 with same target prices.